379 related articles for article (PubMed ID: 17333449)
1. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
Ström O; Borgström F; Sen SS; Boonen S; Haentjens P; Johnell O; Kanis JA
Osteoporos Int; 2007 Aug; 18(8):1047-61. PubMed ID: 17333449
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Johnell O; Jönsson B; Jönsson L; Black D
Pharmacoeconomics; 2003; 21(5):305-14. PubMed ID: 12627984
[TBL] [Abstract][Full Text] [Related]
4. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
Osteoporos Int; 2005 Dec; 16(12):1883-93. PubMed ID: 16133649
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071
[TBL] [Abstract][Full Text] [Related]
7. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Reginster JY
Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
[TBL] [Abstract][Full Text] [Related]
8. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
13. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
18. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
Borgström F; Jönsson B; Ström O; Kanis JA
Osteoporos Int; 2006 Dec; 17(12):1781-93. PubMed ID: 17009083
[TBL] [Abstract][Full Text] [Related]
19. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Schwenkglenks M; Lippuner K
Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
